Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
[the_ad id="32629"]
Home » Page 2

Development & Evaluation E-HIPI HoLISTIC Consortium Report [ASH 2023]

Hodgkin Lymphoma 2 Mins Read

In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a study on predicting progression-free survival…

Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023]

Other 1 Min Read

In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics in pediatric ALL patients. The…

Phase 3 IsKia trial of Isatuximab+ KRd in Multiple Myeloma [ASH 2023]

Multiple Myeloma 1 Min Read

Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate…

Daratumumab in Smoldering Multiple Myeloma Phase 2 CENTAURUS [ASH 2023]

Multiple Myeloma 1 Min Read

At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center,…

Mosunetuzumab 1st Line Follicular Lymphoma Phase 2 [ASH 2023]

Lymphoma 1 Min Read

Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi, a medical doctor and lymphoma…

Efgartigimod in Thrombocytopenia Phase 3 ADVANCE IV Trial Results [ASH 2023]

Other 2 Mins Read

At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown Lombardi Comprehensive Cancer Center at…

Liso-Cel and ctDNA in LBCL Phase 3 TRANSFORM Study

Lymphoma 2 Mins Read

By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical doctor and professor of medicine…

Luspatercept ESA in LR-MDSPhase 3 MEDALIST Study

Other 2 Mins Read

By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical doctor and associate professor of…

Teclistamab Outpatient Admin in Multiple Myeloma

Multiple Myeloma 2 Mins Read

By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers,…

Fertility Preservation: Interrupting endocrine therapy to attempt pregnancy in Breast Cancer

Breast Cancer 2 Mins Read

By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director…

IFN-alpha and plasmacytoid dendritic cells in TNBC FinXX Trial

Other 1 Min Read

By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of triple-negative breast cancer (TNBC), will…

Practice patterns for sequential use of antibody-drug conjugate after antibody-drug

Breast Cancer 2 Mins Read

Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University…

Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Acute Lymphoblastic Leukemia 1 Min Read

By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from…

Marstacimab in Hemophilia: Phase 3 Basis Trial Results

Other 2 Mins Read

At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at McMaster University, shedding light on…

Phase 1 Trial of Alpha-Lactalbumin Vaccine in High Risk in TNBC – SABCS 2023

Breast Cancer 2 Mins Read

Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical…

Palbociclib + Aromatase Inhibitors in MBC w/ Cardiovascular Diseases

Breast Cancer 2 Mins Read

Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor,…

The Top 5 SABCS 2023 Presentations

Breast Cancer 1 Min Read

Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in…


Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688

Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH

Chronic Lymphocytic Leukemia 2 Mins Read

Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical…

Investigating survivin as a novel target for immunotherapy – SABCS 2023

Breast Cancer 2 Mins Read

Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast…

Triple-Negative Breast Cancer Recent Advances – Melinda Telli, MD [SABCS 2023]

Breast Cancer 2 Mins Read

By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD,…

Phase 2 KEYLYNK-009 StudyPembrolizumab + Olaparib mTNBC

Breast Cancer 2 Mins Read

By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California,…

Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 Practice patterns for sequential use of antibody-drug conjugate after antibody-drug 1

Breast Cancer 2 Mins Read

By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North…

Fertility Preservation and assisted reproductive technologies (ART) – SABCS 2023

Breast Cancer 3 Mins Read

By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients…

Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MD

Breast Cancer 3 Mins Read

Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD -…

Mechanical Conditioning score is higher in circulating tumor cells

Breast Cancer 1 Min Read

By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed…


Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688

NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes – Terry Mamounas, MD [SABCS 2023]

Breast Cancer 2 Mins Read

By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP…

Cancer risk associated with exogenous hormone use in BRCA – SABCS 2023

Other 2 Mins Read

By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher from the Women’s College Research…

SABCS 2023 Highlights with Virginia Kaklamani, MD

Other 2 Mins Read

By: Virginia Kaklamani, MD Date: 12/8/2023 Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology and Oncology…

Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors – SABCS 2023

Breast Cancer 2 Mins Read

By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics,…

Combination endocrine therapy following first-line progression

Breast Cancer 2 Mins Read

By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in…

Remodeling microenvironment promotes a tumor-permissive locale for ER+ breast cancer – SABCS 2023

Breast Cancer 2 Mins Read

By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of…

Hormone Replacement Strategies in Women at Moderate to High Risk for Breast Cancer – SABCS 2023

Breast Cancer 2 Mins Read

By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will…

OLAnzaPiNE-3: Low-Dose vs Standard-Dose Olanzapine in Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy in Solid Tumor

Breast Cancer 2 Mins Read

By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will…

SWOG 18: Dasatinib Combo for Older Patients with Ph+ ALL – Long-Term Follow-Up

Other 2 Mins Read

By. Anjali Advani, MD Date. 12/06/2023 In this conversation on OncologyTube, viewers can explore the SWOG 18 clinical trial with…

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL

Other 3 Mins Read

By: Anjali Advani, MD Date: 12/06/2023 Dive into this insightful conversation with Dr. Anjali Advani, a distinguished medical oncologist and…

Onvansertib: Cardiff Oncology’s First-Line Colorectal Cancer Breakthrough with Pfizer

Colorectal 2 Mins Read

By. Fairooz F. Kabbinavar, MD, FACP​ Date. 12/06/2023 Fairooz F. Kabbinavar, MD, FACP, a medical oncologist with a background in…

Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josina Reddy, MD ESMO [2023]

Non-Small Cell Lung Cancer 2 Mins Read

By. Josina Reddy, MDDate. 11/24/2023Today, the focus is on the ALINA trial, a phase three study comparing Alectinib versus chemotherapy…

OVHIPEC-1 Phase 3 Trial: Cytoreductive Surgery in Advanced Ovarian Cancer Lot Aronson, MD

Ovarian 3 Mins Read

By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands…

Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023]

Immunotherapy 2 Mins Read

By. Anusha Kalbasi, MDDate. 11/22/2023In a recent discussion on adoptive T cell therapies for solid tumors, Anusha Kalbasi, MD, provided…

Targeting Tumor Microenvironment Bridget Keenan, MD MOASC [2023]

Immunotherapy 2 Mins Read

By. Bridget Keenan, MDDate. 11/22/2023Bridget Keenan, MD, discusses the tumor microenvironment (TME) and its crucial role in cancer immunotherapy responses.…

Intratumoral Therapy Bartosz Chmielowski, MD MOASC [2023]

Other 2 Mins Read

By. Bartosz Chmielowski, MD PhDDate: 11/22/2023In this presentation, Bartosz Chmielowski, MD PhD, discusses advancements in cancer therapy, focusing on approaches…

O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response – Anna M. Wu, MD – MOASC [2023]

Immunotherapy 1 Min Read

By. Anna M. Wu, MD, PhDDate. 11/21/2023Anna M. Wu, MD, PhD, discussed the use of immunotherapy in patients who underwent…

Radiation and Immunotherapy Combinations – Arta Monjazeb, MD – MOASC [2023]

Non-Small Cell Lung Cancer 2 Mins Read

By. Arta Monjazeb, MDDate: 11/21/2023Arta Monir Monjazeb, MD, explores cancer immunotherapy with a detailed discussion on the immune response, radiation’s…

Immunotherapy for Solid Organ Transplants and Autoimmune Diseases MOASC [2023] Greg Daniels, MD

Other 2 Mins Read

By. Greg Daniels, MD Date: 11/21/2023 In this discussion, Dr. Greg Daniels, a physician in the field of solid organ…

Long and Short Term Toxicity Management in Immuno-Oncology – MOASC [2023] – Katy Tsai, MD

Melanoma Skin Cancer Treatment 2 Mins Read

By. Katy Tsai, MDDate: 11/21/2023Katy Tsai, MD, discusses the progress in cancer survivorship on a national scale, citing data from…

NTRK+ NSCLC: Treatment Options and Side Effects – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Future of RET+ NSCLC Treatment – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Safety and Toxicity of Selpercatinib Versus Pralsetinib – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

RET Fusion Treatment: Pralsetinib – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

RET Fusion Treatment: Selpercatinib – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Rare Fusions in NSCLC: RET – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Treatment Options & Study Data for Patients with ROS1+ NSCLC- Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Treatments and Study Data for Patients with ALK+ NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

High PD-L1:Wait for Genetic Testing Results Before Treatment?-Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Why Some Patients Remain on TKIs Without Acquiring Resistance? – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: What Are the Platform Options for SBRT? – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: What Do We Know About Prevention and Causes of Lung Cancer?-Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: What Can Patients Do to Close the Biomarker Testing Gap?-Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

What Are Some Local Therapy Options for Patients with NSCLC? – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Resistance on Targeted Therapy: Questions Patients Should Ask-Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: Are There Ongoing Trials for Rare NSCLC Mutations? – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: Is Biomarker Testing Common in Early Stage NSCLC? – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: What TT Options Exist for Patients with Driver Mutations? – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: Does Radiation Increase Toxicity for Patients on TT? – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Q&A: Can a Patient Receive SBRT if Unable to Hold Their Breath? – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Local Therapy for Patients After Frontline Therapy – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Future of Local Therapy – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Local Therapy for Patients with Oligoprogressive NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Local Therapy for Limited Metastatic NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Local Therapy for Limited Metastatic NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Adding to Targeted Therapy: Current Statistics and Biology – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Role of the Patient as Advocate – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Treatment for Patients with Locally Advanced Unresectable NSCLC – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Before Surgery, Patients with Resectable NSCLC & Driver Mutation – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Immunotherapy for Patients with Resectable NSCLC & Driver Mutation-Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Alina Trial for ALK+ NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Alina Trial for ALK+ NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Key Points from the Adaura Trial: Osimertinib – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Adaura Trial: The Effect on EGFR+ Treatment – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Biomarker Driven Therapy for NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Barriers to Biomarker Testing: Cost and Insurance – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Barriers to Biomarker Testing: Ordering Tests – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Amivantamab Combo in EGFR Exon 20 NSCLC: PAPILLON Results Nicolas Girard, MD

Non-Small Cell Lung Cancer 2 Mins Read

By. Nicolas Rigard, MDDate. 11/20/2023In this interview, Nicolas Girard, MD, a medical doctor and professor of respiratory medicine at Versailles,…

The Role of Immunotherapy in Patients with Brain Metastases – Kim Margolin, MD

Immunotherapy 2 Mins Read

By. Kim Margolin, MDDate. 11/17/2023In the field of cancer immunotherapy, Kim Margolin, MD, provides insights into the interplay between the…

Tyrosine Kinase Inhibitors: Renal and Prostate Cancer – ESMO 2023

Other 1 Min Read

By. Joaquim Bellmunt, MD, PhD Date. 11/17/2023 At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain,…

EGFR Mutation Progression: Second-Line Lung Cancer Treatments

Non-Small Cell Lung Cancer 2 Mins Read

By. Crispin Hiley, PhD Date. 11/17/2023 Crispin Hiley, PhD, from the UCL Cancer Institute in London, UK, discusses developments in…

Gynecological cancers at ESMO 2023 – Mansoor Raza Mizra, MD

Other 2 Mins Read

By. Mansoor Raza Mizra, MD Date. 11/16/2023 At ESMO this year, Mansoor Raza Mizra, MD, a figure in gynecologic oncology,…

EGFR Mutations: Amivantamab Combo in 1L NSCLC

Non-Small Cell Lung Cancer 2 Mins Read

By. Nicolas Girard, MD Date: 11/15/2023 In a significant development in the field of oncology, Nicolas Girard, MD, played a…

Immuno-Oncology Determining Optimal Treatment Duration – Allison Betof Warner, MD

Melanoma Skin Cancer Treatment 10 Mins Read

By: Allison Betof Warner, MD, PhD, StanfordDate: 11/13/2023 From: MOASCImmuno-Oncology Determining Optimal Treatment Duration Transcript: The question of how long…

Datopotamab deruxtecan in advanced NSCLC TROPION-Lung01 Phase 3

Non-Small Cell Lung Cancer 2 Mins Read

By. Aaron E. Lisberg, MD, Date. 11/14/2023 During ESMO 2023, Aaron E. Lisberg, MD, delivered a presentation on the results…

Sotorasib + Panitumumab in KRAS G12C CodeBreak 300 Phase 3 Trial

Colorectal 2 Mins Read

By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an…

KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast Cancer?

Breast Cancer 2 Mins Read

By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast…

T-DXd HER2 New Insights for Breast Cancer – Funda Meric-Bernstam, MD – ESMO 2023

Other 2 Mins Read

By. Funda Meric-Bernstam, MD Date. 10/11/2023 LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors. Professor Funda…

Cabozantinib in the CABINET Trial: NET Results – Yennifer Chan, MD – ESMO 2023

Other 3 Mins Read

By. Yennifer Chan, MD Lisa Yen, MD Courtesy: LACNETS Date. 11/09/2023 Cabozantinib in the CABINET Trial: NET…

Top 4 ESMO Trials: KEYNOTE 671, CHECKMATE 816, ALINA, TROPION

Non-Small Cell Lung Cancer 3 Mins Read

By: Dr. Rahul Gusain, MD Dr. Rohit Gusain, MD Dr. Joshua Reuss, MD Date:…

2023 Targeted Therapies in Lung Cancer Patient Forum SPANISH Full Vid on Demand

Lung Cancer Treatment 1 Min Read

The full video from the Spanish Targeted Therapies in Lung Cancer Patient Forum 2023 is available now to view ONDemand,…

Current Recommendations and Best Practices for Biomarker Testing – Targeted Therapies in Lung Cancer

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Biomarkers in NSCLC – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

The Importance of Biomarker Testing: What is Liquid Biopsy? – Targeted Therapies in Lung Cancer 2023

Lung Cancer Treatment 1 Min Read

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…

Full Event Mainstage 2023 Targeted Therapies in Lung Cancer Patient Forum ON-DEMAND

Lung Cancer Treatment 1 Min Read

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday,…

Breakout Second Stage 2023 Targeted Therapies in Lung Cancer Forum ON-DEMAND

Lung Cancer Treatment 1 Min Read

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday,…

Amivantamab MARIPOSA Phase 3 results ESMO 2023

Non-Small Cell Lung Cancer 2 Mins Read

By: Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, Date: 11/03/2023 Courtesy: VJOncology Above is a video from Byoung…

Carrick Therapeutics: Samuraciclib + Elacestrant Phase 2 Trial in Breast Cancer

Breast Cancer 2 Mins Read

By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology.…

Uveal Melanoma: Tebentafusp three-year overall survival data Phase 3 KIMMTRAK trial

Melanoma Skin Cancer Treatment 2 Mins Read

By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly…

Phase 3 LEAP-014: Treatment Progress for Metastatic Esophageal Cancer at ESMO 2023

Other 1 Min Read

By. Corina Dutcus, MDDate. November 02, 2023Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic…

Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition

Prostate Cancer Treatment 2 Mins Read

By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact…

NATALEE Trial ESMO 2023: Guideline Changes?

Breast Cancer 2 Mins Read

By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into…

Phase 3 Study 309/KEYNOTE-775: Advanced Endometrial Cancer-ESMO 2023

Other 2 Mins Read

By. Corina Dutcus, MDDate. November 01, 2023Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development…

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

---- 1 Min Read

Mariposa-2: Amivantamab Following Progression on Osimertinib in EGFR-Mutated NSCLC

Lung Cancer Treatment 2 Mins Read

Author: Dr Antonio Passaro (on-camera comments) – Courtesy of ESMO.org At the ESMO 2023 conference, the results of the Phase three…

MATTERHORN Trial Highlights the Transformative Potential of Durvalumab + FLOT in Gastric and GEJ Cancer Treatment

Other 1 Min Read

Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort,…

Amivantamab: Phase III MARIPOSA-2 combo vs chemotherapy in EGFR-mutated advanced NSCLC

Non-Small Cell Lung Cancer 2 Mins Read

By. Antonio Passaro, MDDate. October 31, 2023Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in…

HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023

Small Cell Lung Cancer 2 Mins Read

By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key…

Anti-TIGIT Therapy: Balancing Promise and Challenges in Unleashing Potential.

Immunotherapy 2 Mins Read

By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD…

Lenvatinib Analysis on Advanced ccRCC Treatment at ESMO 2023

Other 2 Mins Read

By. Corina Dutcus, MDDate. October 30, 2023In this video interview, Corina Dutcus, MD, will address pivotal aspects of phase 3…

CheckMate 901: Nivolumab/Chemo Sets New Standard for Metastatic Urothelial Carcinoma

Other 2 Mins Read

Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment…

LITESPARK-005 Study: Belzutifan for Metastatic Clear Cell Renal Cell Carcinoma

Other 2 Mins Read

Dr Laurence Albiges (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, an individual presented a study at the forefront…

Selpercatinib in RET+ NSCLC: LIBRETTO-431

Non-Small Cell Lung Cancer 3 Mins Read

Author: Dr Herbert Ho Fung Loong (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, I’ve had the pleasure of presenting…

Lu-PSMA-617 in mCRPC: PSMAfore Trial – ESMO 2023

Prostate Cancer Treatment 2 Mins Read

Author: Dr. Oliver Sartor (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, an opportunity arose to present new data…

Alectinib ALK positive NSCLC: The ALINA study

Lung Cancer Treatment 2 Mins Read

Author: Professor Ben Solomon (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, the speaker had the pleasure of presenting the…

Pembro + CRT in Adv. Cervical Cancer: KEYNOTE-A18

Cervical 2 Mins Read

Author: Dr. Domenica Lorusso (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, the results of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial were…

Durvalumab + olaparib 45% Reduction Disease Progression in Endometrial – ESMO 2023

Cervical 2 Mins Read

By. Shannon Westin, MDDate. October 27, 2023In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E…

Tisotumab Vedotin vs. Investigator’s Choice in Cervical Cancer – ESMO 2023

Cervical 3 Mins Read

By. Brian SlomovitzDate. October 26, 2023 Brian Slomovitz, MD, presented insights into the innovaTV 301 study and its implications for…

Libtayo Sets a New Standard for CSCC Treatment at ESMO 2023

Melanoma Skin Cancer Treatment 2 Mins Read

By. Neil Gross, MDDate. October 26, 2023 In a discussion detailing the primary outcomes of the Phase 2 trial for…

Phase 3 EMBARK: Enzalutamide + Leuprolide Prostate Cancer ESMO 2023

Prostate Cancer Treatment 2 Mins Read

By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore…

Sacituzumab Govitecan in Advanced HNSCC – ESMO 2023 -Loren Michel

Head and Neck 3 Mins Read

By: Loren Michel, MD Date: October 25, 2023 At the recent ESMO conference, Dr. Loren Michel presented the results of…

Enfortumab Vedotin & Bladder Cancer: Thomas Powles, MD ESMO 2023

Bladder 2 Mins Read

By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator…

Sarclisa Phase 2 GMMG-CONCEPT Carfilzomib, Lenalidomide, and Dexamethasone

Multiple Myeloma 3 Mins Read

By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands…

Prognostic Models in Myelofibrosis Management Slides 2023

Myeloproliferative Disease 4 Mins Read

By: Abdulraheem Yacoub MD Date: October 25, 2023 In a prestigious medical conference hall filled with experts in the field of…

Hodgkin Lymphoma: Harnessing Hope through Advances in Research

Hodgkin Lymphoma 2 Mins Read

By: Elizabeth Brem, MD Date: October 06, 2023 Elizabeth Brem, MD, began her talk by addressing some disclosures she had…

Myelofibrosis alternative treatments – Slides 2023

Myeloproliferative Disease 2 Mins Read

By: John Mascarenhas, MD Date: October 04, 2023 John Mascarenhas, MD, stands as a distinguished authority in the realm of…

Mantle Cell Lymphoma: Insights and Challenges Slides 2023

Lymphoma 2 Mins Read

By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her…

Tackling Carboplatin Shortages 2023: Ensuring Uninterrupted Cancer Care

General 14 Mins Read

Preventing a Carboplatin Shortage: Strategies to Ensure Cancer Drug Availability in 2023 In an era where advancements in cancer treatment…

Unlocking Dostarlimab in Endometrial Cancer

Ovarian 10 Mins Read

Harnessing the Power of Dostarlimab to Treat Advanced or Recurrent Endometrial Cancer Endometrial cancer remains a significant challenge for medical…

GeoVax: A Gedeptin Update 2023 – David Dodd

Immunotherapy 2 Mins Read

GeoVax, a pioneering healthcare company, has developed a groundbreaking product known as GADEPTIN. GADEPTIN is a cutting-edge therapy designed to…

Myelofibrosis Patients with Low Platelet Counts – [Slides 2023]

Myeloproliferative Disease 3 Mins Read

By: Allen WilbanksDate: October 01, 2023 In a conference room filled with medical professionals and researchers, the audience leaned forward,…

T Cell Lymphomas: Advances and Challenges – [Slides 2023]

Lymphoma 2 Mins Read

By: Allen WilbanksDate: October 02, 2023 In a comprehensive discussion led by the esteemed Swami Lyer, MD, the focus centered…

TTFields Therapy Offers New Hope in Metastatic Non-Small-Cell Lung Cancer Treatment: Insights from the LUNAR Phase 3 Study.

Non-Small Cell Lung Cancer 3 Mins Read

By: Allen Wilbanks Date: September 29, 2023 In the groundbreaking Phase 3 LUNAR study led by Dr. Ticiana Leal, MD,…

What are your thoughts on the overall impact of TTFields treatment on the lives of patients with lung cancer?

Non-Small Cell Lung Cancer 1 Min Read

Allen Wilbanks asked Ticiana Leal, MD from the Winship Cancer Institute of Emory University, about her thoughts on the overall…

What are the ongoing challenges and areas for future research in the use of TTFields for lung cancer?

Non-Small Cell Lung Cancer 1 Min Read

Ticiana Leal, MD, a distinguished oncologist from the Winship Cancer Institute of Emory University, shared her insights during a discussion…

Essential Thrombocythemia: Diagnosis, Risk- [slides 2023]

Myeloproliferative Disease 2 Mins Read

By: Allen Wilbanks Date: September 29/2023 At the conference, Pankit expressed gratitude for another great talk, saying, “Thank you, Pankit…

Ribociclib Impact on Early Breast Cancer Treatment

Breast Cancer 2 Mins Read

In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed…

AVEO Oncology Fotivda Video Pre-Roll

Kidney 1 Min Read

AVEO Oncology Fotivda Video Pre-Roll

What is the long-term efficacy and safety of TTFields treatment for lung cancer?

Non-Small Cell Lung Cancer 2 Mins Read

In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised…

How does TTFields treatment compare to other treatments for NSCLC, such as surgery, radiation therapy, and chemotherapy?

Non-Small Cell Lung Cancer 1 Min Read

In a recent discussion, Ticiana Leal, MD, sheds light on TD Fields treatment for non-small cell lung cancer. This innovative…

Advancements in Bispecific Antibodies [2023 slides]

Lymphoma 2 Mins Read

By: Allen Wilbanks Date: September 28/2023 Paolo Strati, MD, an assistant professor at the Anderson Cancer Center in Houston, Texas, delivered…

Potential of JAK Inhibitors in Myelofibrosis [2023 slides]

Myeloproliferative Disease 2 Mins Read

By: Allen Wilbanks Date: September 28, 2023 Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect.…

Relapse Refractory Hodgkin lymphoma [slides 2023]

Hodgkin Lymphoma 2 Mins Read

By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr.…

Are there any specific patient subgroups who may benefit more or less from TTFields treatment?

Acute Lymphoblastic Leukemia 1 Min Read

Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks…

What are the implications of the LUNAR trial findings for clinical practice?

Non-Small Cell Lung Cancer 2 Mins Read

In this informative video, viewers will gain valuable insights into the groundbreaking research discussed by medical experts Ticiana Leal, MD,…

Pacritinib: Anemia Mechanisms in MPNs -NFKB/ACVR1- [2023 SLIDES]

Hematologic Malignancies 2 Mins Read

By: Allen Wilbanks Date: September 27, 2023 Stephen Oh, MD PhD, took the podium to present his research in a…

MRD: Revolutionizing Lymphoma Care – [2023 SLIDES]

Lymphoma 2 Mins Read

By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal…

What were the key findings of the LUNAR trial? – Ticiana Leal, MD

Non-Small Cell Lung Cancer 2 Mins Read

In a groundbreaking lunar trial, Ticiana Leal, MD, a distinguished expert from the Winship Cancer Institute of Emory University, spearheaded…

How do tumor treating fields (TTFields) work? – Ticiana Leal MD

Acute Lymphoblastic Leukemia 1 Min Read

Ticiana Leal, MD, is at the forefront of an intriguing and evolving discussion centered on the mechanism underlying tumor treating…

Myeloproliferative Neoplasms: WHO/ICC Systems – [2023 SLIDES]

Hematologic Malignancies 2 Mins Read

By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction…

Follicular Lymphoma: Treatment and Quality of Life-[2023 SLIDES]

Lymphoma 3 Mins Read

By: Allen Wilbanks Date: September 27 /2023 John Leonard, MD, a prominent figure in the field of oncology, delivered a…

Tyrosine Kinase Inhibitors in Mastocytosis-[2023 SLIDES]

Hematologic Malignancies 2 Mins Read

By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work…

Genomic Profiling and Strategies for Blood Cancer- [2023 SLIDES]

Hematologic Malignancies 2 Mins Read

By: Allen Wilbanks Date: 09/27/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available…

Myeloid Neoplasms with Eosinophilia and TK Fusion Genes [Slides] 2023

Hematologic Malignancies 3 Mins Read

By: Pankit Vachhani, MD Date: 09/22/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…

Diffuse Large B Cell Lymphoma-What is best for risk prediction and treatment? [2023 Slides].

Chronic Lymphocytic Leukemia 2 Mins Read

By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for…

Checkmate 227 Reveals Six-Year Survival Advantages of Nivolumab + Ipilimumab in mNSCLC

Non-Small Cell Lung Cancer 2 Mins Read

In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing…

AML-ALL US Focus 2023, La Jolla, July 7-8 2023 – Version 2

Bladder 1 Min Read

an AML-ALL US Focus Meeting 2023 video

FLAURA2: Should this Positive Trial Change Practice for EGFRm+ NSCLC

Non-Small Cell Lung Cancer 2 Mins Read

Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive…

Akadeum: What is a T Cell Activation & Expansion Kit?

General 2 Mins Read

In a discussion with Allen Wilbanks from Oncology Tube, Brandon McNaughton, CEO & Founder of Akadeum Life Sciences, shed light…

TTFields Phase 3 LUNAR Trial Results in Metastatic NSCLC – Ticiana Leal, MD

Non-Small Cell Lung Cancer 2 Mins Read

In the pivotal phase 3 LUNAR study, Ticiana Leal, MD, and her colleagues made a groundbreaking discovery that could revolutionize…

What is the significance OneOncology’s pathways?

General 2 Mins Read

OneOncology, a rapidly expanding national platform for independent medical practices, proudly announces the completion of 25 distinctive oncology and hematology…

irAEs and TRBV polymorphisms – Interview with Timothy Looney, PhD

Immunotherapy 2 Mins Read

Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic…

Cancer Immunotherapy Advances: Jill O’Donnell – Tormey, PhD

General 2 Mins Read

The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential…

TIBSOVO’s Potential: Susan Pandya, MD, on FDA Priority Review for IDH1-Mutated MDS

Acute Myelogenous Leukemia 1 Min Read

In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and…

Lonsurf: FDA Approval with Bevacizumab – Marwan Fakih, MD

Colorectal 2 Mins Read

Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of…

CD8 T cells effectively kill cancer cells – Joshua Brody, MD

General 2 Mins Read

Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine…

Axatilimab in Chronic Graft-Versus-Host Disease AGAVE 201 Results.

Bone Metastases 3 Mins Read

In the interview with Allen Wilbanks of OncologyTube, Peter Langmuir, the Vice President of Oncology Drug Development at Incyte, discussed…

FDA Grants Full Approval for Mirvetuximab Soravtansine-gynx (Elahere) for FRα positive, platinum-resistant epithelial ovarian with Robert Coleman, MD

Ovarian 4 Mins Read

The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the…

UGN-102 – Top line Phase 3 study results – Mark Schoenberg, MD

Bladder 3 Mins Read

Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma…

Updates in Lymphoma [2023] Interview – Elizabeth Brem, MD – MOASC

Lymphoma 2 Mins Read

Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to…

Updates in Head and Neck Cancer [2023] Interview – Shirin Attarian, MD – MOASC

Head and Neck 2 Mins Read

Shirin Attarian, MD addresses the escalating incidence of head and neck cancer and highlights that most cases, particularly oropharyngeal cancers,…

Updates in GU [2023] Interview – Mar, MD – MOASC

Bladder 1 Min Read

Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO…

Niraparib Treatment in Patients With Advanced Ovarian Cancer

Ovarian 1 Min Read

Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research…

Pre-Roll Example

Other 1 Min Read

Pre-Roll Example

Advertise on Oncology: Book Now for Limited Time Discounts

Other 2 Mins Read

Advertising on OncologyTube For A Limited Time No Contracts! Pay As You Go! Book Now! or Contact Us for More Info…

Sanam Loghavi , MD- Innovations in Hematopathology

Acute Myelogenous Leukemia 1 Min Read

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center,…

Yasmin Abaza, MD- AML and MDS: Challenges and Future Directions

Acute Myelogenous Leukemia 1 Min Read

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of…

Interview Jessica Altman, MD-Triplet-Based vs. Sequential Therapy

Acute Myelogenous Leukemia 1 Min Read

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern…

Interview Elias Jabbour- Advances in Survival and Immunotherapy

Acute Lymphoblastic Leukemia 1 Min Read

Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour,…

Astellas Sponsored Expert Discussion- MD Education

Acute Myelogenous Leukemia 1 Min Read

The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance…

Bijal Shah,MD,MS[slides] UPD-CART Cell Therapy for Refractory ALL

Acute Lymphoblastic Leukemia 1 Min Read

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…

Charles Mullighan,MD[slides]-Genomic Classification-Corrected

Acute Lymphoblastic Leukemia 1 Min Read

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves…

Updates in Breast Cancer [2023] Interview – Lavasani, MD MOASC

Breast Cancer 3 Mins Read

Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused…

Regina Myers, MD[slides]-CART Cell-Relapse and Antigen Modulation

Acute Lymphoblastic Leukemia 2 Mins Read

Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses…

Shira N. Dinner, MD [slides]- Therapies for Older Adult ALL

Acute Lymphoblastic Leukemia 1 Min Read

Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment…

Hagop Kantarjian, MD[slides]- ALL Treatment:Therapies-Strategies

Acute Lymphoblastic Leukemia 1 Min Read

Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…

How To Support Your Patients’ Mental Health After a Blood Cancer Diagnosis

Hematologic Malignancies 2 Mins Read

When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that…

Imidix

Lung Cancer Treatment 1 Min Read

Nitin Jain, M.D [slides]-CD7 CAR-T and LCK Inhibition Strategies

Acute Lymphoblastic Leukemia 2 Mins Read

Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer…

Bijal Shah, MD, MS [slides]- CART Cell Therapy for Refractory ALL

Acute Lymphoblastic Leukemia 1 Min Read

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…

Marina Konopleva, MD, PhD [slides]- PH-like all- MD Education

Acute Lymphoblastic Leukemia 1 Min Read

Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and…

Marlise Luskin,MD, MSCE [slides]-Venetoclax and BCL2 Inhibitors

Acute Lymphoblastic Leukemia 1 Min Read

Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The…

Elias Jabbour, MD [slides]-Exploring Blina, CAR T-Cell Strategies

Acute Lymphoblastic Leukemia 1 Min Read

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD…

IMpower010 Unveiled: A Fresh Look at Atezolizumab in Lung Cancer

Non-Small Cell Lung Cancer 10 Mins Read

IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially…

Ryan Cassaday,MD[slides]-Inotuzumab/Blinatumomab in Older Adults

Acute Lymphoblastic Leukemia 1 Min Read

Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the…

Anjali Advani, MD [slides]- Blinatumomab into Upfront Therapy

Acute Lymphoblastic Leukemia 2 Mins Read

Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the…

Aaron Logan, MD, PhD [slides] – Leukemia Treatment via MRD

Acute Lymphoblastic Leukemia 1 Min Read

Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude…

ASCO FCR Guidelines: Evaluating Advanced Prostate Cancer Eligibility – Jalen Patel, MD – MOASC

Prostate Cancer Treatment 1 Min Read

Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the…

Urothelial Cancer Eligibility: ASCO-FCR Recommendations – Dukkipati, MD – MOASC

Bladder 2 Mins Read

Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis…

Mark Litzow, MD[slides]-Transplantation Necessity-Novel Therapy

Acute Myelogenous Leukemia 1 Min Read

Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude…

Branko Cuglievan, MD [slides]- AML: Insights on Menin Inhibition

Acute Myelogenous Leukemia 2 Mins Read

Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer…

Charles Mullighan,MD[slides]-Genomic Classification/B-Cell/T-Cell

Acute Lymphoblastic Leukemia 2 Mins Read

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude…

Elias Jabbour, MD[slides]- TKIs and Immunotherapy- MD Education

Acute Lymphoblastic Leukemia 2 Mins Read

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered…

Wendy Stock, MD[slides]- Improving AYA ALL Outcomes- MD Education

Acute Lymphoblastic Leukemia 2 Mins Read

Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock,…

Marina Konopleva,MD[slides]- Resistance Mechanisms and Strategies

Acute Myelogenous Leukemia 1 Min Read

Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation…

Tapan Kadia, MD[slides]- AML: Strategies for Long-Term Remission

Acute Myelogenous Leukemia 1 Min Read

Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation…

Hetty Carraway, MD [slides] Immune Innovations in MDS

Acute Myelogenous Leukemia 1 Min Read

Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel…

Andrew Artz MD [slides]- Strategies in Transplant and Maintenance

Acute Myelogenous Leukemia 1 Min Read

Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the…

Yasmin Abaza, MD [slides]-CD123 Targeting and Innovative CAR T Research

Acute Myelogenous Leukemia 2 Mins Read

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute…

Ghassan Abou-Alfa, MD – HIMALAYA Phase III trial – Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.m4v

Liver 3 Mins Read

Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key…

Is the Oncology Community Too Accepting of Marketing Messages in Cancer Trials? A Close Look at IMpower010

Non-Small Cell Lung Cancer 2 Mins Read

Dr. Jack West,MD an associate professor in medical oncology at City of Hope Comprehensive Cancer Center in Los Angeles, discussed…

Naval Daver MD [slides]-Triple-Drug Protocols/ Molecular Subtypes

Acute Myelogenous Leukemia 1 Min Read

Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses…

Brian Andrew Jonas, M.D., Ph.D.- HMA-Venetoclax for MDS/AML

Acute Myelogenous Leukemia 1 Min Read

Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation…

Jessica Altman, MD -Therapeutic Approaches and Patient Well-being

Acute Myelogenous Leukemia 1 Min Read

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies…

Neoadjuvant Chemo: Insights & Its Role in Cancer Care

Non-Small Cell Lung Cancer 21 Mins Read

In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of…

Courtney DiNardo, MD- Innovative Combinations of IDH Inhibitors

Acute Myelogenous Leukemia 1 Min Read

Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…

Eytan M. Stein, MD- Revumenib & Ziftomenib- Menin Inhibitors

Acute Myelogenous Leukemia 1 Min Read

Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia…

What is the function of the RCC1?[2023 Slides] Warnecke, DO – MOASC

General 3 Mins Read

Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of…

irAE in CKD [2023 Slides] – Dalia Kaakour, MD – MOASC

Kidney 3 Mins Read

Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and…

Toripalimab + Gemcitabine in NPC [2023 Slides] Attarian, MD – MOASC

Head and Neck 5 Mins Read

Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as…

Alexander Edward Perl, MD- FLT3 and Therapeutic Resistance

Acute Myelogenous Leukemia 1 Min Read

Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward…

Advertise to Oncologists on OncologyTube.com

Help 1 Min Read

Farhad Ravandi, MD- The Impact of Minimal Residual Disease

Acute Myelogenous Leukemia 1 Min Read

Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in…

Refresh URL Changing Content

Other 1 Min Read

Refresh URL Changing Content

TROP2 ADC in NSCLC [2023] slides Sai-Hong Ignatius Ou, MD – MOASC

Non-Small Cell Lung Cancer 3 Mins Read

Spotlight on Oncology: Exploring the Latest Advances in Lung Cancer Research Date: August 12, 2023 Speaker: Sai-Hong Ignatius Ou, MD…

Brentuximab v. Nivolumab cHL SWOG S1826 [Slides] Brem, MD – MOASC

Non-Hodgkin Lymphoma 4 Mins Read

Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving…

Pankit Vachhani, MD – Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Bone Metastases 2 Mins Read

Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine Timestamps: 0:00:09 What is the objective of this study on indolent…

Amir T. Fathi MD [slides]- IDH 1/2-Mutant AML Treatment

Acute Myelogenous Leukemia 1 Min Read

Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…

Harry Erba, MD [slides]- The Survival Impact of Quizartinib

Acute Myelogenous Leukemia 2 Mins Read

Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who…

Joseph D. Khoury, MD- AML [slides]: Genetic Insights

Acute Myelogenous Leukemia 1 Min Read

Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…

Talazoparib and Enzalutamide TALAPRO-2 Results [2023] Slides – Mar, MD – MOASC

Genitourinary 4 Mins Read

The “MOASC SPOTLIGHT ON ONCOLOGY – GU ASCO UPDATES” seminar, led by Dr. Nataliya Mar, Clinical Associate Professor in the…

NAPOLI-3 Trial NALIRIFOX [2023] Slides – Chung, MD – MOASC

Pancreatic 3 Mins Read

Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an…

IMbrave150 Trial Results – Slides [2023] El-Khoueiry, MD – MOASC

Genitourinary 4 Mins Read

Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris…

PROSPECT Trial Phase 3 Results [Slides] – Jason Zell, DO – MOASC

Colorectal 2 Mins Read

MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor,…

What is the best treatment for HR+ breast cancer? [2023] – Lavasani – MOASC

Breast Cancer 2 Mins Read

Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of…

Sacituzumab Govitecan: A New Dawn in Cancer Care

Bladder 9 Mins Read

In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise…

Sanam Loghavi [slides]- AML Diagnosis & Molecular Insights

Acute Myelogenous Leukemia 2 Mins Read

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer…

AML-ALL US Focus 2023, La Jolla- Version 1- Elias Jabbour MD

Acute Lymphoblastic Leukemia 1 Min Read

For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform.…

S6 Saturday Debate 1 Discussion Corrected – Blinatumomab

Acute Lymphoblastic Leukemia 1 Min Read

The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical…

Session 6 Panel Discussion Corrected Version -NGS-MRD Detection

Acute Myelogenous Leukemia 1 Min Read

The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease…

Session 8 Panel Discussion-Nelarabine’s Efficacy- MD-Education

Acute Lymphoblastic Leukemia 1 Min Read

In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion…

S7 Debate 2 Discussion- CAR T-cell/Inotuzumab for Relapsed ALL

Acute Lymphoblastic Leukemia 1 Min Read

In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing…

Honoring Dr. Krystal Cascetta, Devoted Cancer Researcher

News 2 Mins Read

We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to…

Session 7 Panel Discussion -Venetoclax and Novel Therapies

Acute Myelogenous Leukemia 1 Min Read

The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies.…

ASP-1929: A Bright Horizon for Head & Neck Cancer Treatment

Head and Neck 11 Mins Read

When discussing the myriad of cancers that affect humans, head and neck cancers, though slightly less talked about, remain a…

Previous 1 2 3 4 … 50 Next
Recent Posts
  • ESMO 2025 Top 10 Breast Cancer Abstracts: 10 Positive Breakthroughs
  • TCR-T Therapy: 49% Risk Cut & 39% Response
  • ESMO 2025 Top 10 Genitourinary Cancer Must-See Abstracts: 78% rPFS Boost Unveiled
  • Immune Checkpoint Inhibitors Myocarditis: 1% Risk, 50% Fatal – UCSF Insights
  • TIL Therapy Breakthroughs for Oncologists and Oncology Professionals
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
© 2025 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.